Kinarus Therapeutics (SIX:KNRS) is a clinical-stage pharmaceutical company focused on bringing novel, patient-focused treatments for viral, respiratory, and ophthalmic diseases. Kinarus was incorporated in Basel, Switzerland in 2017. Our lead drug candidate is an oral combination of a clinical-stage P38 mitogen activated protein kinase (p38 MAPK) inhibitor, in-licensed from Roche, and a second drug, together enabling an oral, long-term effective treatment. Kinarus has launched a large Phase 2 clinical trial in hospitalized Covid-19 patients with the aim to reduce mortality and duration of hospital stay. The mechanism of action of our candidate is three-fold; reducing viral replication, inflammation, and organ damage. The trial is actively enrolling patients. Kinarus has also obtained regulatory approval for a one-year Phase 2 clinical trial in patients diagnosed with wet Age-Related Macular Degeneration. Injectable agents targeting vascular endothelial growth factor are the only approved therapies. Despite the availability of these drugs, real-world data shows significant under-treatment leading to progressive loss of vision and blindness. Kinarus's drug candidate, administered on top of anti-VEGF agents, has the potential to reduce injection frequency, providing additional therapeutic benefit and relieving the high burden to patients and their caregivers.
View Top Employees from Kinarus TherapeuticsWebsite | https://www.kinarus.com/ |
Revenue | $4 million |
Employees | 5 (1 on RocketReach) |
Founded | 2017 |
Address | Technologiepark Basel 60c Hochbergerstrasse, Basel, Basel-City, CH |
Phone | +41 61 633 29 71 |
Technologies |
JavaScript,
HTML,
PHP
+7 more
(view full list)
|
Industry | Biotechnology Research, Manufacturing General, Biopharma, Manufacturing, Biotechnology, Health Care, Science and Engineering, Wellness |
SIC | SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 3254 Companies, NAICS Code 32 Companies, NAICS Code 325 Companies, NAICS Code 32541 Companies |
Looking for a particular Kinarus Therapeutics employee's phone or email?
The Kinarus Therapeutics annual revenue was $4 million in 2024.
1 people are employed at Kinarus Therapeutics.
Kinarus Therapeutics is based in Basel, Basel-City.
The NAICS codes for Kinarus Therapeutics are [3254, 32, 325, 32541].
The SIC codes for Kinarus Therapeutics are [283, 28].